

November 7, 2019

Carl Firth, Ph.D.  
Chief Executive Officer  
ASLAN Pharmaceuticals Ltd.  
83 Clemenceau Avenue #12-03 UE Square  
Singapore

Re: ASLAN Pharmaceuticals Ltd.  
Registration Statement on Form F-3  
Filed October 31, 2019  
File No. 333-234405

Dear Dr. Firth:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Paul Fischer at 202-551-3415 with any questions.

Sincerely,  
Division of  
Office of Life

Corporation Finance  
Sciences  
cc: Robert Phillips